Organization
Corbus Pharmaceuticals, Inc.
3 abstracts
Abstract
Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.Org: Hebei University Affiliated Hospital, Affiliated Cancer Hospital of Harbin Medical University, Jiamusi Cancer and Tuberculosis Hospital, Phase I Clinical Trials Center, CSPC Pharmaceutical Group Limited,
Abstract
A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositisOrg: Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Corbus Pharmaceuticals, Inc.,
Abstract
BASELINE EUROPEAN PATIENT DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 3 STUDY OF SAFETY AND EFFICACY OF LENABASUM, A CB2 AGONIST, IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSISOrg: Corbus Pharmaceuticals, Inc., Hospital for Special Surgery Main Hospital,